Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RPA1 | P27694 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148840 | 0.92 | PTGS2 (0.50) | MALT1PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL5152212 | 0.87 | MALT1 (0.51) | MALT1PTGS2SMOGRIA2RPA1 | |
| SCHEMBL5149081 | 0.86 | MALT1 (0.44) | MALT1PTGS2PTGS1SMORPA1 | |
| SCHEMBL5148640 | 0.86 | PTGS2 (0.54) | MALT1PTGS2PTGS1CNR2 | |
| SCHEMBL5152420 | 0.86 | PTGS2 (0.42) | MALT1PTGS2PTGS1ALDH1A1 | |
| SCHEMBL5149129 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL5147886 | 0.84 | SMO (0.47) | MALT1SMORPA1 | |
| SCHEMBL5152238 | 0.83 | SMO (0.46) | MALT1PTGS2PTGS1SMORPA1 | |
| SCHEMBL14504588 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1ABCB11ALDH1A1FYN | |
| SCHEMBL5148806 | 0.83 | MALT1 (0.42) | MALT1PTGS2PTGS1GRIA2RPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1567503-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20040116475-A1 | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2004050632-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | MALT1 1227/4885PTGS2 1780/4885PTGS1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.